Cuba launches clinic for chikungunya aftereffects

The Institute of Neurology and Neurosurgery in Cuba has begun a specialized clinic to care for patients with post-chikungunya ailments, particularly those linked to neuropathic pain, joint pain, and paresthesia. This step provides focused treatment for individuals impacted by the mosquito-borne virus.

In Havana on December 23, the Institute of Neurology and Neurosurgery in Cuba has launched a specialized clinic dedicated to treating patients with post-chikungunya ailments. The facility focuses on conditions such as neuropathic pain, joint pain, and paresthesia, which are common lingering effects of the mosquito-borne chikungunya virus that causes fever and severe aches.

Chikungunya can lead to long-term complications that impair daily life for those infected. The new clinic aims to address these persistent issues through comprehensive care. As reported by Prensa Latina, this opening meets the demand for specialized health services in Cuba.

While specific patient numbers are not yet available, the clinic is part of Cuba's public health efforts to manage infectious diseases and their neurological aftermaths. This initiative highlights Cuba's dedication to accessible medical treatment for virus-related conditions.

Articoli correlati

Comparative illustration of long COVID patients: US woman with severe brain fog and anxiety versus milder symptoms in India, Nigeria, and Colombia, per international study.
Immagine generata dall'IA

International study finds U.S. long COVID patients report more brain fog and psychological symptoms than peers in India and Nigeria

Riportato dall'IA Immagine generata dall'IA Verificato

A Northwestern Medicine-led study of more than 3,100 adults with long COVID found that non-hospitalized participants in the United States reported substantially higher rates of brain fog, depression/anxiety and insomnia than participants in Colombia, Nigeria and India—differences the researchers say likely reflect cultural factors and access to care as much as biology.

Il presidente cubano Miguel Díaz-Canel ha presentato risultati preliminari positivi dalle prove cliniche del farmaco biotecnologico Jusvinza in pazienti con artrite cronica post-chikungunya. Gli studi, avviati a dicembre 2025, mostrano miglioramenti notevoli in province come L'Avana e Matanzas. Gli esperti evidenziano il profilo di sicurezza del farmaco e il suo potenziale per rallentare l'infiammazione.

Riportato dall'IA

Cuba ha una situazione epidemiologica favorevole nella lotta contro gli arbovirus, dopo una diminuzione del 21% dei casi febbrili segnalati la settimana scorsa. Questo miglioramento evidenzia gli sforzi efficaci per controllare le malattie trasmesse da vettori come la dengue e la zika. Le autorità sanitarie sottolineano la necessità di una vigilanza continua.

New research challenges long-standing concerns about the antiviral drug oseltamivir, known as Tamiflu, and its potential link to serious neuropsychiatric events in children. Instead, the study attributes such symptoms to the influenza virus itself and shows that Tamiflu treatment halves the risk of these complications. The findings, based on a large analysis of pediatric health records, aim to reassure families and doctors about the drug's safety.

Riportato dall'IA

A genetic technology called a gene drive has shown promise in preventing malaria transmission by mosquitoes during lab tests in Tanzania. Researchers modified local mosquitoes to produce antimalarial proteins, demonstrating effective inhibition of parasites from infected children. The findings suggest the approach could work in the field if released.

Il progetto Hatuey, un'iniziativa di solidarietà con base negli Stati Uniti, ha consegnato donazioni di forniture e farmaci per il trattamento del cancro pediatrico a due ospedali cubani. Si tratta dell'ottava volta che supportano il sistema sanitario dell'isola in mezzo al blocco economico statunitense. Il coordinatore del progetto ha riaffermato un impegno incrollabile verso Cuba durante un evento all'Avana.

Riportato dall'IA Verificato

Scientists at the University of Queensland have captured the first near‑atomic, high‑resolution 3D images of the yellow fever virus, detailing how the surface of the long‑used vaccine strain differs from virulent, disease‑causing strains. The work sheds light on how the virus is recognised by the immune system and could support improved vaccines for yellow fever and related mosquito‑borne diseases.

 

 

 

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta